Evaluation of Diagnosis and Treatment of Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia with Predictive Marker Identification

What this Trial Is About

Researchers are studying autoimmune cytopenias, including autoimmune hemolytic anemia, immune thrombocytopenia, and chronic idiopathic/autoimmune neutropenia, to better understand how these conditions are diagnosed and treated. The study also includes a subgroup of patients with myelodysplastic syndromes to investigate immune activation and red blood cell metabolism. The goal is to evaluate diagnostic tools, treatment types, responses, and predictors of outcomes over time. Participants will be observed without receiving experimental treatments. They will undergo clinical and laboratory evaluations such as immunohematology, cytokine assays, bone marrow studies, molecular tests, and fecal microbiome analysis. Patients will be sampled at diagnosis and followed for at least three years to track their clinical course, therapies used, response rates, relapses, and any complications like infections or thromboses. Throughout the study, participants will provide samples including peripheral blood and feces for detailed laboratory analyses. Researchers will assess the sensitivity and specificity of diagnostic tests and monitor various biological markers, including cytokine levels and somatic mutations. Data on treatment safety and effectiveness in routine practice will be collected, and participants will be regularly monitored for up to three years to understand the progression and outcomes of their conditions.

Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia